Universitat Heidelberg

The European Atomic Energy Community (euratom), Represented by the European Commission

The European Community, Represented by the European Commission

The European Union, Represented by the European Commission

Alfred Morgenstern

Christos Apostolidis

Uwe Haberkorn

Frederik Giesel

Roger Molinet

Clemens Kratochwil

Frank Bruchertseifer

Klaus Luetzenkirchen

Klaus Lützenkirchen

The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.

Treatment of PMSA expressing cancers

Methods of using Th-226 or mother radionuclides thereof, namely U-230 or Th-226, in medicine. These radionuclides are particularly appropriate for the treatment of human and/or non-human mammals, in particular for therapeutic, diagnostic (detection/imaging), prophylactic and pain palliation purposes. These radionuclides may be used in various forms for treatment and/or diagnostic purposes, in particular in cationic form or in the form of radioconjugates or bone-targeting complexes. Methods of making such radionuclides.

Radionuclides for medical use

Growing community of inventors

Karlsruhe, Germany

Alfred Morgenstern